Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504008 | 0.92 | DDB1 (0.59) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL3625138 | 0.91 | DDB1 (0.50) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL31268245 | 0.86 | DDB1 (0.50) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL14124937 | 0.85 | DDB1 (0.56) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4962412 | 0.85 | DDB1 (0.56) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL7383260 | 0.84 | DDB1 (0.55) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL1966881 | 0.81 | KMT2A (0.52) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL13311996 | 0.81 | DDB1 (0.56) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3497895 | 0.80 | DDB1 (0.55) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL31268167 | 0.79 | DDB1 (0.50) | DDB1CRBNALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118892553-A | Esatitecan analogue, ligand-drug conjugate thereof and application thereof | 浙江大学 | 2024-11-05 | — | — | CN | disclosed |
| EP-1893579-B1 | 1-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-05-01 | — | — | EP | disclosed |
| US-7816380-B2 | 1-hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME LLC | 2009-03-05 | — | — | US | disclosed |
| EP-1893579-A1 | 1-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006132837-A1 | l-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, HRH4 | DDB1 1821/4885CRBN 2159/4885ALDH1A1 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.